NEW YORK (GenomeWeb News) – Enzo Biochem today said that it has entered into a supply and distribution deal with privately held Cancer Genetics (CGI) covering the use of Enzo Life Sciences' fluorescent dye labels for increasing signal intensity in labeling nucleic acids.
Under the non-exclusive agreement, Enzo Life Sciences will incorporate its labels into CGI's nucleic acid material that it and supplies to the research market.
Rutherford, NJ-based CGI has developed and sells DNA FISH probes and CGH microarrays for use in cancer diagnostics in the lab setting.
"This agreement enables us to offer our labeling products in conjunction with Cancer Genetics' FISH probes, which are highly regarded in the research market, and which also provide strong recognition for our technology," Carl Balezentis, president of the Enzo Life Sciences division of Enzo Biochem, said in a statement. "We also recognize that opportunities exist to expand our clinical lab offerings through the unique products and services for personalized cancer treatment being offered and being developed by CGI."
Financial and other terms of the alliance were not disclosed.